Dual antiplatelet therapy for acute coronary syndromes: How long to continue?
For patients with an acute coronary syndrome event, current guidelines recommend dual antiplatelet therapy for at least 12 months after drug-eluting stent placement. However, several clinical trials have assessed whether continuing dual antiplatelet therapy beyond 12 months is beneficial. We review the pros and cons of extending dual antiplatelet therapy.
MedStar Heart and Vascular Institute, MedStar Washington Hospital Center, Washington, DC, USA. E-mail: meghanahalkar@gmail.com.
Meghana
M
Halkar
Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, USA.|Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.
A Michael
AM
Lincoff
D054058:Acute Coronary Syndrome / Q000188:drug therapy*; D004359:Drug Therapy, Combination / Q000379:methods; D006801:Humans; D054539:Medication Therapy Management / Q000592:standards; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D013997:Time Factors
D010975:Platelet Aggregation Inhibitors